Companies / Circio Holding ASA
CRNA.OLCircio Holding ASA
3 active clinical studies registered on ClinicalTrials.gov, the most advanced in Phase 2. Next estimated primary completion: 19 May 2027.
Clinical pipeline
| Primary completion | Phase | Status | Condition and study |
|---|---|---|---|
| Dec 2024 passed |
Phase 2? | Active, not recruiting | Pancreas Cancer Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer · NCT05638698 |
| 19 May 2027 | Phase 1/2? | Recruiting | Multiple Myeloma, Smoldering Multiple Myeloma The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma · NCT05841550 |
| Jun 2027 | Phase 2? | Active, not recruiting | Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer · NCT06015724 |
Source: ClinicalTrials.gov, studies with the company as sponsor and an active status. Data fetched 7 October 2026.
Recent news
Headlines from other publications, linked to the original. We do not rewrite or summarise them. Analyst ratings and price targets are the opinion of the cited source, not ours.
- CRNA Forecast — Price Target — Prediction for 2027
- Circio Holding ASA: Issuance of restricted stock units (RSUs) to the board members
- Circio Holding To Cancel Subsequent Offering
- Circio Holding ASA: Cancellation of Subsequent Offering
- Circio Holding ASA (CRNA) Cancels Planned NOK 200M Subsequent Offering
- Circio Holding ASA: Cancellation of Subsequent Offering
- Circio Holding ASA: Registration of share capital increase following private placement of approximately NOK 200 million
- Circio Holding ASA (CRNA) Registers NOK 200M Private Placement
- Circio Holding ASA(OB: CRNA) added to S&P Global BMI Index
- Circio Raises NOK 200 Million to Accelerate Circular RNA Platform Development
- Circio raises ~$21M to fund in vivo CAR-T therapy push
- Private Placement at NOK 200 Million with 9% Discount to Support circVec In Vivo CAR-T Therapy Programme